Evidence map›Paper›PMID 38896183›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2024

Androgen deprivation therapy in advanced prostate cancer: insights from a real-world patient survey on health-related quality of life and information and communication sources.

Renée Bultijnck, Luc De Laere, Rony De Grande, Thijs Develter, Sophie Vantieghem, Pieter Uvin, Christophe Ghysel, Bram De Laere, patient organization Think Blue Vlaanderen vzw

Abstract read
PubMed Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Renée Bultijnck *Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
Luc De Laere *Department of Urology, AZ Sint-Jan Hospital, Brugge, Belgium.
Rony De GrandeThink Blue Vlaanderen vzw, Brugge, Belgium.
Thijs DevelterDepartment of Urology, AZ Sint-Jan Hospital, Brugge, Belgium.
Sophie VantieghemDepartment of Urology, AZ Sint-Jan Hospital, Brugge, Belgium.
Pieter UvinDepartment of Urology, AZ Sint-Jan Hospital, Brugge, Belgium.
Christophe GhyselDepartment of Urology, AZ Sint-Jan Hospital, Brugge, Belgium.
Bram De LaereDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium. bramdlae.DeLaere@ugent.be.ORCID http://orcid.org/0000-0002-1174-0384
patient organization Think Blue Vlaanderen vzw

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAndrogen deprivation therapy (ADT) is a cornerstone treatment for advanced and metastatic prostate cancer. Real-world and patient-reported insights into ADT's impact on health-related quality of life (HRQoL) and communication experiences in healthcare settings remain underexplored. This patient organisation-initiated online survey aimed to assess these aspects.

methodsBetween December 2022 and August 2023, the patient organisation Think Blue Vlaanderen and the AZ Sint-Jan Hospital (Bruges, Belgium) invited ADT-treated patients to participate in a prospective, online, cross-sectional, patient-reported outcome survey. Demographic, clinical, HRQoL (FACT and EPIC-26), communication sources and information modality data were collected. Descriptive statistics and comparative analyses were applied.

resultsA total of 276/312 (88.5%) participating patients were on ADT at time of survey administration and completion, with the majority receiving a 3-monthly regimen. Sexual HRQoL was low and narrowly distributed (median (IQR): 16.7 (16.7-16.7)), with 84% of patients having erectile dysfunction (ED). Patients finding their ED problematic were more likely to seek pharmaceutical treatment. Hormonal HRQoL was widely distributed (median (IQR): 65 (45-85)), which improved with prolonged ADT duration. Physically active patients reported less lack of energy, but increased hot flashes. Within consistent FACT-G summary scores (median (IQR): 64.50 (54.75-77.00)), improved emotional wellbeing with prolonged ADT was noted. Multidisciplinary communication and multimodal information provision improved patient satisfaction.

conclusionPatient organisation-initiated surveys offer real-world and patient-reported insights. Patient-tailored HRQoL assessments and longitudinal follow-up, physical activity, and multidisciplinary and multimodal communication approaches are warranted to improve patient-centred care in patients receiving ADT.

Indexed as

Androgen AntagonistsPatient Reported Outcome MeasuresProstatic NeoplasmsQuality of LifeAgedAged, 80 and overBelgiumCommunicationCross-Sectional StudiesHumansMaleMiddle AgedProspective StudiesSurveys and QuestionnairesAndrogen AntagonistsADTEPIC26FACTHealthcare communicationHRQoLPatient organisationPatient-reported outcomes

Identifiers

PMID38896183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.